Skip to main content

Table 1 Baseline characteristics

From: An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod

Parameter Mean (SD) Median Range
 Age (years) 48 (12) 47 28–67
 Weight (kg) 65 (9) 66 50–79
 Height (cm) 169 (8) 170 157–184
 Sex    
  Female (n) 7
  Male (n) 2
 Disease duration (months) since    
  Onset of Raynaud’s phenomenon 32 (38) 17 2–120
  Onset of skin involvement 20 (16) 16 8–58
 mRSS 28 (10) 25 19–46
 QoLa    
  HAQ-DI 1.1 (0.6) 1.0 0.5–2.2
  SF-36 Physical component sum 35 (12) 37 17–48
Parameter Yes No Unknown
 Antinuclear antibody (ANA) positive (n) 9 0 0
 Anti-RNA polymerase III positive (n) 3 5 1
 Anti-topoisomerase I positive (n) 5 3 1
 Lung fibrosis (by high-resolution CT) (n) 3 6 0
 Pitting scars (n) 4 5 0
 Digital ulcers (n) 1 8 0
 Ongoing corticosteroid treatmentb (n) 3 6 0
 Previous immunosuppressive treatment (n) 0 9 0
  1. SD standard deviation
  2. aQoL-HAQ-DI is a disability index ranging from 0 to 3 where 0 means that certain activities can be done without difficulty and 3 means that these activities cannot be done at all. SF-36 is a health index where 0 means maximum disability and 100 means no disability. The SF-36 Physical component sum is a calculated score based on different questions related to physical health
  3. bIndication was joint involvement in all 3 patients and doses equivalent to < 10 mg prednisolone per day